Daewon Pharmaceutical Co., Ltd. (KRX:003220)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,120
-310 (-2.71%)
At close: Mar 3, 2026
-20.85%
Market Cap 244.98B
Revenue (ttm) 590.70B
Net Income (ttm) -16.04B
Shares Out 21.43M
EPS (ttm) -748.20
PE Ratio n/a
Forward PE 32.20
Dividend 300.00 (2.62%)
Ex-Dividend Date Dec 29, 2025
Volume 51,033
Average Volume 44,670
Open 11,340
Previous Close 11,430
Day's Range 11,120 - 11,400
52-Week Range 11,120 - 15,350
Beta 0.20
RSI 32.45
Earnings Date Mar 17, 2026

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t... [Read more]

Sector Healthcare
Founded 1958
Employees 1,283
Stock Exchange Korea Stock Exchange
Ticker Symbol 003220
Full Company Profile

Financial Performance

In 2024, Daewon Pharmaceutical's revenue was 598.16 billion, an increase of 13.51% compared to the previous year's 526.95 billion. Earnings were 14.21 billion, a decrease of -40.59%.

Financial Statements

News

There is no news available yet.